Skip to main content
main-content

06-07-2022 | JAK inhibitors | Ask the expert | Video

How to talk to patients about JAK inhibitor safety

share
SHARE

Speaker: Victoria Ruffing

Following the results of the ORAL Surveillance trial, which demonstrated increased rates of adverse events in people taking JAK inhibitors, Victoria Ruffing provides guidance on how to talk to patients about the risks associated with these medications (6:42).

Related content

11-08-2021 | JAK inhibitors | Feature | Article

JAK inhibitor safety: Distilling the evidence

Peter Nash discusses the latest evidence on the association between JAK inhibitors and the risk for VTE, MACE, and malignancy